Valeant investor Doyle departs Pershing Square to focus on Novocure
“Given our dynamic growth, we believe there is significant value in expanding Bill’s role as an executive officer at Novocure as we work together to establish Tumor Treating Fields, or TTFields, as a new treatment modality for a variety of solid tumors. Since his initial involvement in 2003, Bill’s leadership has been instrumental in setting the company’s strategic direction as we’ve worked together to build the immediate commercial opportunity for TTFields in glioblastoma and to develop TTFields as a potential treatment for other solid tumors,” CEO Asaf Danziger said in a press release.
DeviceTalks Minnesota's leadership track is designed to provide attendees with insights on topics such as:
Use code SAVE15 to save 15%!